Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →A data-led view of the membrane bioreactor patent landscape: filing trends since 2017, technology composition across IPC classes, leading assignees and where white space remains for new claims.
Filing growth = 2021 (808 records) → 2024 (474); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 9,149 records in scope (CR5), not the ranked leaders only.
Membrane bioreactor (MBR) filings sit almost entirely inside water and wastewater treatment claim language rather than bioreactor apparatus language. Across 9,149 records published between 2015 and the 2026 cut-off, the dominant IPC subclass is C02F — water and wastewater treatment — at 96.3% of records, with B01D separation processes (filtration) the next most common at 24.6%. Classes tied to fermentation or microorganism engineering, such as C12M and C12N, each sit under 2% of records, which tells a filer that the crowded claim space is process and membrane-separation integration, not the biological apparatus itself.
China dominates the receiving-office split by a wide margin, followed at much smaller volume by the United States, the European Patent Office, WIPO's PCT route, South Korea and Australia. That distribution, combined with a long tail of single-digit filers behind a modest leader, points to a technology where the core separation mechanics are well documented but commercial deployment and regional adaptation claims remain fragmented.
Publication lags filing by roughly 18 months, so the most recent one or two years in any chart will always look lower than they will eventually settle — read the tail of the trend accordingly.
Filings climbed from 520 in 2017 to a peak of 808 in 2021, then declined 41% to 474 by 2024 — the last year with complete publication data. Because 2025 and 2026 are still filling in, this should be read as cooling from an unusually dense filing peak, not as an early signal that interest in the technology is ending.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
C02F (water & wastewater treatment) appears in 96.3% of the 9,149 records in scope, and B01D (separation processes) in 24.6%. Every other class — bioreactor apparatus, mixing, microorganism engineering, cleaning and fermentation — sits at or below 1.8% of records, confirming that MBR patenting is overwhelmingly framed as a treatment-process problem with membrane separation as the enabling mechanism.
Shares are the percentage of the 9,149 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about membrane bioreactor patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaA wastewater treatment system built around a facultative-organism-adapted membrane bioreactor: a reaction vessel, a membrane separation system inside it, a water production system that pumps filtrate out of the membrane separation system, and an aeration system. The method aerates the reaction vessel so that dissolved oxygen concentration across more than 50% of the vessel volume stays below 1 mg/L, coupling low-oxygen biological conditioning with in-vessel membrane filtration.Filed by Jiangxi JDL Environmental Protection, 2017-09-07 — see the chat answer below for what this claim set blocks.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US7172699B1 | Energy efficient wastewater treatment for nitrogen and phosphorus removal | 204 |
| 2 | US6361695B1 | Shipboard wastewater treatment system | 178 |
| 3 | US5254253A | Modular shipboard membrane bioreactor system for combined wastewater streams | 165 |
| 4 | US20070209999A1 | Wastewater treatment system and method | 158 |
| 5 | US4885087A | Apparatus for mass transfer involving biological/pharmaceutical media | 158 |
| 6 | US20060201876A1 | Filtration apparatus comprising a membrane bioreactor and a treatment vessel for digesting organic materials | 155 |
| 7 | US6616843B1 | Submerged membrane bioreactor for treatment of nitrogen containing water | 142 |
| 8 | US20030201225A1 | Organic slurry treatment process | 139 |
| 9 | US6692642B2 | Organic slurry treatment process | 134 |
| 10 | US20050045557A1 | Method for treating wastewater in a membrane bioreactor to produce a low phosphorus effluent | 131 |
Citation counts favour older records simply because they have had longer to accumulate citations inside the searched corpus — treat them as a signal of influence on later filings, not as a ranking of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Four figures from this dataset matter more than the rest for anyone deciding where to file or partner next.
The ranked leader holds 106 records and the top 10 assignees combined account for only 8.0% of all 9,149 records in scope. That is a genuinely fragmented field — freedom-to-operate risk is spread across many small filers rather than concentrated behind one or two blocking portfolios.
Filings peaked at 808 in 2021 and eased to 474 by 2024, the last complete year. Given the ~18-month publication lag, 2025–2026 figures are still filling in and should not be read as continued decline.
Almost every record in scope is classified under C02F water and wastewater treatment, with B01D separation processes a distant second at 24.6%. Apparatus-focused classes like C12M bioreactors sit near 1.8%, so drafting strategy in this space should anchor on treatment-process claims first.
China's receiving office accounts for the large majority of filings in scope, with the United States, EPO, WIPO/PCT, South Korea and Australia each receiving a much smaller share. A portfolio strategy built only around US/EP filing will miss most of the documented activity in this field.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to membrane bioreactor patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Tongji University | Shanghai Chengtou Wastewater Treatment Co., Ltd. | 22 |
| General Electric Company | BL Technology Inc. | 12 |
| General Electric Company | WANG SIJING | 11 |
| Jiangxi JDL Environmental Protection Co., Ltd. | Shenzhen JDL Investment Management Co., Ltd. | 10 |
| Tongji University | Shanghai Zizheng Environmental Protection Technology Co., Ltd. | 9 |
| Siemens Water Technologies | ZUBACK JOSEPH E | 4 |
| Siemens Water Technologies | SMITH GEORGE W | 4 |
| Siemens Water Technologies | JORDAN EDWARD J | 4 |
Ten co-assignee pairs are recorded in this dataset; the strongest links a university and a municipal wastewater operator, and another pairs an established water-technology multinational with a domestic partner — a pattern consistent with applied-research-to-utility deployment rather than pure corporate R&D.
The numbers above tell you where the claim space is dense and where it is thin. Turning that into a defensible filing or freedom-to-operate position takes closer reading of the actual claim language.
Run your draft claims against the densest IPC clusters — C02F and B01D — to see exactly which limitations are already occupied and which are open.
Explore claims in Eureka →With no filer above single-digit share of the field, watch for consolidation signals — acquisitions or licensing moves — among the mid-tier assignees rather than assuming the nominal leader sets the pace.
Monitor assignees in Eureka →The most-cited records in this set are decades old in places; confirm which of their claims are still live before assuming they block a new filing.
Review cited patents in Eureka →This dataset counts 9,149 published records in scope between 2015 and the 2026 cut-off, searched across water-treatment and separation-process IPC classes (C02F and B01D). Filings rose from 520 in 2017 to a peak of 808 in 2021, then eased to 474 by 2024, the last year with complete publication data. Because publication lags filing by roughly 18 months, the 2025–2026 figures will continue to rise as more applications publish.
The ranked leader in this dataset holds 106 records, but concentration is low overall: the top 5 assignees combined account for only 4.5% of all 9,149 records, and the top 10 for 8.0%. That means no single company or research institute dominates the field — filing activity is spread across a long tail of national and regional players, many with single-digit portfolios. Anyone assessing freedom-to-operate risk should look at the full ranked set rather than assume one or two names control the space.
The overwhelming majority of records, 96.3%, sit under IPC class C02F (water and wastewater treatment), with B01D (separation processes such as filtration) the next most common at 24.6%. Apparatus-specific bioreactor classes like C12M and microorganism-engineering classes like C12N each account for under 2% of records. In practice this means most MBR claim sets are written around the treatment process and the membrane-separation step integrated into it, rather than around fermentation or bioreactor hardware in isolation.
Filings peaked in 2021 at 808 and declined 41% to 474 by 2024, which is the most recent year that can be treated as complete given the roughly 18-month publication lag. That decline from a peak does not necessarily mean underlying R&D interest is falling — it may reflect a filing surge around 2021 that has since normalised. The 2025 and 2026 figures in any chart will keep rising as later applications publish, so they should not be read as evidence of a continuing drop.
The technology composition data shows heavy claim density in water-treatment process language (C02F, 96.3% of records) and filtration/separation mechanics (B01D, 24.6%), which suggests those branches carry the thickest prior art. Classes tied to microorganism engineering (C12N), mixing/stirring hardware (B01F) and fermentation-specific synthesis (C12P) each sit at or below roughly 1% of records, indicating comparatively thin coverage. A first claim built around control logic linking membrane fouling response to a specific microbial or fermentation parameter is one plausible under-claimed combination worth checking against live art before drafting.
Go past this page: query the whole membrane bioreactor patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page